Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 3/20 | 0.41 |
| ▸ | HTR2B | P41595 | 3/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28291020 | 0.94 | ASIC3 (0.43) | PNMTHTR2CHTR2BHTR2AHRH3 | |
| SCHEMBL26963045 | 0.86 | HRH3 (0.47) | PNMTHTR2CHTR2BHTR2AHRH3 | |
| SCHEMBL4573212 | 0.84 | CARM1 (0.42) | PNMTHRH3CARM1ABHD6 | |
| SCHEMBL26963061 | 0.82 | ASIC3 (0.44) | PNMTHTR2CHTR2BHTR2AHRH3 | |
| SCHEMBL30658395 | 0.82 | ASIC3 (0.44) | PNMTHTR2CHTR2BHTR2AHRH3 | |
| SCHEMBL29501433 | 0.81 | SLC18A3 (0.50) | HTR2CHTR2BHTR2ATAAR1 | |
| SCHEMBL22860678 | 0.78 | HTR2C (0.46) | HTR2CHTR2BHTR2AHRH3CYP2D6 | |
| SCHEMBL30508272 | 0.77 | PRMT5 (0.39) | PNMTHRH3CARM1ABHD6 | |
| SCHEMBL2675953 | 0.76 | HTR2C (0.56) | HTR2CHTR2BHTR2ACYP2D6NOS3 | |
| SCHEMBL6632323 | 0.75 | RAD52 (0.51) | HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246909-A1 | EBNA1 Inhibitors and Methods Using Same | WISTAR INST (US) | 2024-07-25 | — | — | US | disclosed |
| US-11912659-B2 | EBNA1 inhibitors and methods using same | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2024-02-27 | — | — | US | disclosed |
| US-20220064112-A1 | EBNA1 Inhibitors and Methods Using Same | WISTAR INST (US) | 2022-03-03 | — | — | US | disclosed |
| CN-113149885-A | EBNA1 inhibitors and methods of using the same | 威斯塔解剖学和生物学研究所 | 2021-07-23 | — | — | CN | disclosed |
| EP-3294705-B1 | EBNA1 INHIBITORS AND METHODS USING SAME | WISTAR INST (US) | 2021-07-21 | — | — | EP | disclosed |
| US-10981867-B2 | EBNA1 inhibitors and methods using same | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2021-04-20 | — | — | US | disclosed |
| CN-107848964-B | EBNA1 inhibitors and methods of using the same | 威斯塔解剖学和生物学研究所 | 2021-03-19 | — | — | CN | disclosed |
| US-20200239415-A1 | EBNA1 INHIBITORS AND METHODS USING SAME | WISTAR INST (US) | 2020-07-30 | — | — | US | disclosed |
| US-10442763-B2 | EBNA1 inhibitors and methods using same | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180305312-A1 | EBNA1 INHIBITORS AND METHODS USING SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-10-25 | — | — | US | disclosed |
| EP-3294705-A1 | EBNA1 INHIBITORS AND METHODS USING SAME | The Wistar Institute Of Anatomy And Biology (US) | 2018-03-21 | — | — | EP | disclosed |
| WO-2016183534-A1 | EBNA1 INHIBITORS AND METHODS USING SAME | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239415-A1 | EBNA1 INHIBITORS AND METHODS USING SAME | MLLT1, EBNA1BP2, MALT1 | PNMT 3691/4885HTR2C 4851/4885HTR2B 4652/4885 |
| US-20180305312-A1 | EBNA1 INHIBITORS AND METHODS USING SAME | MLLT1, EBNA1BP2, MALT1 | PNMT 3691/4885HTR2C 4851/4885HTR2B 4652/4885 |
| US-10981867-B2 | EBNA1 inhibitors and methods using same | MLLT1, EBNA1BP2, MALT1 | PNMT 3691/4885HTR2C 4851/4885HTR2B 4652/4885 |
| US-20240246909-A1 | EBNA1 Inhibitors and Methods Using Same | MLLT1, EBNA1BP2, MALT1 | PNMT 3691/4885HTR2C 4851/4885HTR2B 4652/4885 |
| US-20220064112-A1 | EBNA1 Inhibitors and Methods Using Same | MLLT1, EBNA1BP2, MALT1 | PNMT 3691/4885HTR2C 4851/4885HTR2B 4652/4885 |
| US-11912659-B2 | EBNA1 inhibitors and methods using same | MLLT1, EBNA1BP2, MALT1 | PNMT 3691/4885HTR2C 4851/4885HTR2B 4652/4885 |
| US-10442763-B2 | EBNA1 inhibitors and methods using same | MLLT1, EBNA1BP2, MALT1 | PNMT 3691/4885HTR2C 4851/4885HTR2B 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.